TET2 and acute myeloid leukemia: Of the 396,065 CpGs available for analysis in the TCGA data, 13,031 associated with the presence of a DNMT3A mutation in our EWAS of AML patients (see Methods; FDR < 0.05), and 12 associated with the presence of a TET2 mutation (FDR < 0.05).